Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation

Irene Gaw Sia, Jennie A. Wilson, Cynthia M. Groettum, Mark J. Espy, Thomas F. Smith, Carlos V. Paya

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) DNA load was analyzed as a marker for relapse of CMV infection in 24 solid organ transplant patients with CMV infection or disease who received a fixed 14-day course of intravenous ganciclovir. Viral load was measured in blood samples obtained before and at the completion of treatment. Eight (33%) of 24 patients developed relapsing CMV infection. Median pretreatment viral loads were higher in the relapsing group (80,150 copies/106 leukocytes) than in the nonrelapsing group (5500 copies/106 leukocytes; P = .007). The relapsing group also had persistent detectable viral DNA (median, 5810 copies/106 leukocytes) after treatment, whereas it was undetectable in the nonrelapsing group (P < .0001). Primary CMV infection (seronegative recipients of seropositive organs, D+R-) was an independent marker for CMV relapse (P = .03), and these patients had higher pre- and posttreatment viral loads than did non-D+/R- patients (P< .0001 and P = .0014, respectively). CMV DNA load is a useful marker for individualizing antiviral treatment of CMV infection in solid organ transplant recipients.

Original languageEnglish (US)
Pages (from-to)717-720
Number of pages4
JournalJournal of Infectious Diseases
Volume181
Issue number2
DOIs
StatePublished - 2000

Fingerprint

Cytomegalovirus Infections
Organ Transplantation
Cytomegalovirus
Viral Load
DNA
Leukocytes
Transplants
Recurrence
Ganciclovir
Viral DNA
Antiviral Agents
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. / Sia, Irene Gaw; Wilson, Jennie A.; Groettum, Cynthia M.; Espy, Mark J.; Smith, Thomas F.; Paya, Carlos V.

In: Journal of Infectious Diseases, Vol. 181, No. 2, 2000, p. 717-720.

Research output: Contribution to journalArticle

Sia, Irene Gaw ; Wilson, Jennie A. ; Groettum, Cynthia M. ; Espy, Mark J. ; Smith, Thomas F. ; Paya, Carlos V. / Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. In: Journal of Infectious Diseases. 2000 ; Vol. 181, No. 2. pp. 717-720.
@article{ef68de608f8e4c1ba12a66e2a56a99d6,
title = "Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation",
abstract = "Cytomegalovirus (CMV) DNA load was analyzed as a marker for relapse of CMV infection in 24 solid organ transplant patients with CMV infection or disease who received a fixed 14-day course of intravenous ganciclovir. Viral load was measured in blood samples obtained before and at the completion of treatment. Eight (33{\%}) of 24 patients developed relapsing CMV infection. Median pretreatment viral loads were higher in the relapsing group (80,150 copies/106 leukocytes) than in the nonrelapsing group (5500 copies/106 leukocytes; P = .007). The relapsing group also had persistent detectable viral DNA (median, 5810 copies/106 leukocytes) after treatment, whereas it was undetectable in the nonrelapsing group (P < .0001). Primary CMV infection (seronegative recipients of seropositive organs, D+R-) was an independent marker for CMV relapse (P = .03), and these patients had higher pre- and posttreatment viral loads than did non-D+/R- patients (P< .0001 and P = .0014, respectively). CMV DNA load is a useful marker for individualizing antiviral treatment of CMV infection in solid organ transplant recipients.",
author = "Sia, {Irene Gaw} and Wilson, {Jennie A.} and Groettum, {Cynthia M.} and Espy, {Mark J.} and Smith, {Thomas F.} and Paya, {Carlos V.}",
year = "2000",
doi = "10.1086/315242",
language = "English (US)",
volume = "181",
pages = "717--720",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation

AU - Sia, Irene Gaw

AU - Wilson, Jennie A.

AU - Groettum, Cynthia M.

AU - Espy, Mark J.

AU - Smith, Thomas F.

AU - Paya, Carlos V.

PY - 2000

Y1 - 2000

N2 - Cytomegalovirus (CMV) DNA load was analyzed as a marker for relapse of CMV infection in 24 solid organ transplant patients with CMV infection or disease who received a fixed 14-day course of intravenous ganciclovir. Viral load was measured in blood samples obtained before and at the completion of treatment. Eight (33%) of 24 patients developed relapsing CMV infection. Median pretreatment viral loads were higher in the relapsing group (80,150 copies/106 leukocytes) than in the nonrelapsing group (5500 copies/106 leukocytes; P = .007). The relapsing group also had persistent detectable viral DNA (median, 5810 copies/106 leukocytes) after treatment, whereas it was undetectable in the nonrelapsing group (P < .0001). Primary CMV infection (seronegative recipients of seropositive organs, D+R-) was an independent marker for CMV relapse (P = .03), and these patients had higher pre- and posttreatment viral loads than did non-D+/R- patients (P< .0001 and P = .0014, respectively). CMV DNA load is a useful marker for individualizing antiviral treatment of CMV infection in solid organ transplant recipients.

AB - Cytomegalovirus (CMV) DNA load was analyzed as a marker for relapse of CMV infection in 24 solid organ transplant patients with CMV infection or disease who received a fixed 14-day course of intravenous ganciclovir. Viral load was measured in blood samples obtained before and at the completion of treatment. Eight (33%) of 24 patients developed relapsing CMV infection. Median pretreatment viral loads were higher in the relapsing group (80,150 copies/106 leukocytes) than in the nonrelapsing group (5500 copies/106 leukocytes; P = .007). The relapsing group also had persistent detectable viral DNA (median, 5810 copies/106 leukocytes) after treatment, whereas it was undetectable in the nonrelapsing group (P < .0001). Primary CMV infection (seronegative recipients of seropositive organs, D+R-) was an independent marker for CMV relapse (P = .03), and these patients had higher pre- and posttreatment viral loads than did non-D+/R- patients (P< .0001 and P = .0014, respectively). CMV DNA load is a useful marker for individualizing antiviral treatment of CMV infection in solid organ transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=0034050770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034050770&partnerID=8YFLogxK

U2 - 10.1086/315242

DO - 10.1086/315242

M3 - Article

VL - 181

SP - 717

EP - 720

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -